RT Journal Article
SR Electronic
T1 Comorbidities and Susceptibility to COVID-19: A Generalized Gene Set Meta-Analysis Approach
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.14.20192609
DO 10.1101/2020.09.14.20192609
A1 Beckman, MF
A1 Igba, CK
A1 Mougeot, FB
A1 Mougeot, J-LC
YR 2020
UL http://medrxiv.org/content/early/2020/09/15/2020.09.14.20192609.abstract
AB Background The COVID-19 pandemic has led to over 820,000 deaths for almost 24 million confirmed cases worldwide, as of August 27th, 2020, per WHO report. Risk factors include pre-existing conditions such as cancer, cardiovascular disease, diabetes, obesity, and cancer. There are currently no effective treatments. Our objective was to complete a meta-analysis to identify comorbidity-associated single nucleotide polymorphisms (SNPs), potentially conferring increased susceptibility to SARS-CoV-2 infection using a computational approach.Results SNP datasets were downloaded from publicly available GWAS catalog for 141 of 258 candidate COVID-19 comorbidities. Gene-level SNP analysis was performed to identify significant pathways by using MAGMA program. SNP annotation program was used to analyze MAGMA-identified genes. COVID-19 comorbidities from six disease categories were found to have significant associated pathways, which were validated by Q-Q plots (p<0.05). The top 250 human mRNA gene expressions for SNP-affected pathways, extracted from publicly accessible gene expression profiles, were evaluated for significant pathways. Protein-protein interactions of identified differentially expressed genes, visualized with STRING program, were significant (p<0.05). Gene interaction networks were found to be relevant to SARS and influenza pathogenesis.Conclusion Pathways potentially affected by or affecting SARS-CoV-2 infection were identified in underlying medical conditions likely to confer susceptibility and/or severity to COVID-19. Our findings have implications in COVID-19 treatment development.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is not a clinical trial.Funding StatementNo external funding for this study was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:I confirm all relevant ethical guidelines have been followed, and the present study was exempt from review as only publicly available data were used.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data for this study is available upon request.ADAMTS9a disintegrin-like and metalloprotease with thrombospondin type 1 motif, 9AHABEadenocarcinoma human alveolar basal epithelialaLFCaverage log-fold changeA-MuLVAbelson murine leukemia virusC127mouse fibroblastCISconfidence interaction scoreCOVID-19coronavirus disease of 2019CTLcytotoxic T-lymphocyteEHMT2euchromatic histone lysine methyltransferase 2FGFR2fibroblast growth factor receptor 2GEOGene Expression OmnibusGIDEONGlobal Infectious Disease and Epidemiology Network databaseGOGene OntologyGWASgenome-wide association studiesHBEhuman bronchial epithelialHEKhuman embryonic kidneyHLA-DRB1major histocompatibility complex, class II, DR Beta 1HLA-DRB5major histocompatibility complex, class II, DR Beta 5HLA-DQA2major histocompatibility complex, class II, DQ Beta 1HLA-DQB1major histocompatibility complex, class II, DQ Beta 1HTLhelper T-lymphocyteHUGOHuman Genome OrganizationIFI30IFI30 lysosomal thiol reductaseIL2RAinterleukin 2 receptor subunit alphaKEGGKyoto Encyclopedia of Genes and GenomesKPNB1karyopherin subunit beta 1MAGMAMulti-marker Analysis of GenoMic AnnotationMDCKmadin-darby canine kidneymiRDBmicroRNA Target Prediction DatabaseNDNo DataNUP153nucleoporin 153NUP160nucleoporin 160PBMCsperipheral blood mononuclear cellsPIK3R2phosphoinositide-3-kinase regulatory subunit 2PMprimary macrophagesPPARGC1Aperoxisome proliferator-activated receptor gamma coactivator 1 alphaPolyPhen2Polymorphism Phenotyping 2Q-Qquantile-quantileSARSsevere acute respiratory syndromeSARS-CoV-1severe acute respiratory syndrome coronavirus-1SARS-CoV-2severe acute respiratory syndrome coronavirus-2SIFTSorting Intolerant from TolerantSLC4A7solute carrier family 4 member 7SLC24A3solute carrier family 24 member 3SNPssingle nucleotide polymorphismsST6GALNAC1ST6-acetylgalactosaminide alpha-2,6-sialytransferase 1ST6GALNAC3ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3STAT1signal transducer and activator transcription 1STAT3signal transducer and activator of transcription 3TAP2transporter 2, ATP binding cassette subfamily B memberVEPVariant Effect PredictorVeroepithelial kidney cells derived from African green monkey (Chlorocebus spp.);WHOWorld Health OrganizationZAP-70zeta-chain associated protein kinase 70